MEDCAC Panel Holds Cards For MDT, SYK

Deutsche Bank writes "[T]he MEDCAC panel is most relevant for Medtronic (NYSE: MDT)(Buy) and to a lesser extent Stryker (NYSE: SYK)(Hold). Medtronic's INFUSE represents 5.5% of total Medtronic sales, while Stryker records a small amount (<2%) sales from its OP-1. We believe the panel's conclusions were as we expected and consistent with the data that is currently available in the market place. We don't see a need at this time to alter our sales expectations for Medtronic's Biologics division."

Medtronic closed yesterday at $33.57.
Stryker closed yesterday at $48.02.

Learn how to find the best stocks to trade each day in our 70 page E-Book and 90 minute online video for free.